In addition to being early to the defense tech and AI trends, Lux has realized significant exits from its investment in AI ...

Gerald Murnane’s Landscape with Landscape opens with a splendidly disgruntled preface. The book is a collection of six ...

There’s something magical about watching movies under the stars, and the Admiral Twin Drive-In in Tulsa delivers that enchantment with a double dose of nostalgia that’ll make you feel like you’ve time ...

In particular, the rally after Gary Gensler’s ousting suggests that the blockchain ecosystem’s value is underpinned by how ...

Recursion Pharmaceuticals (NASDAQ: RXRX), a small-cap biotech company, has one claim to fame: It currently owns the largest ...

NuScale stock is up about 37% in the brand-new year, helped by the Trump administration's recent award of $2.7 billion to ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the 12 Best Genomics Stocks to Invest In. Cathie Wood’s ARK Investment ...

As of Wednesday, December 17, Recursion Pharmaceuticals, Inc.’s RXRX share price has surged by 13.10%, which has investors questioning if this is right time to sell.

The native just-in-time compiler in Python 3.15 can speed up code by as much as 20% or more, although it’s still experimental.